420 with CNW — White House Noncommittal on Biden’s View of DOJ’s Stand on Cannabis Reclassification

The White House hasn’t disclosed whether President Joseph Biden backs the U.S. Department of Justice’s (DOJ) proposal to reclassify cannabis after a review he initiated. During a conversation with Karine Jean-Pierre, the White House press secretary, reporters asked questions regarding the president’s stance on the DOJ’s proposal to shift marijuana from Schedule I to III.

Jean Pierre responded by noting that Biden’s administration would let the review process unfold, so she wouldn’t “preempt the matter.” She also stressed the president’s clear stance against incarcerating individuals solely for cannabis possession. Jean-Pierre has consistently refrained from directly addressing the administration’s stance on the rescheduling proposal. Nonetheless, she noted that the review directed by the president aligns with his promise to voters during the last election.

Biden has granted mass pardons twice to individuals convicted of federal cannabis possession offenses. Reclassifying marijuana to Schedule III wouldn’t legalize it or release individuals currently imprisoned for cannabis-related charges.

It’s worth noting that during his presidential campaign, Biden promised to reclassify cannabis as Schedule II substance, which is a stricter classification than what his administration is considering. Jean-Pierre reiterated that the president’s position on the matter is the reason behind his directive for the U.S. Department of Health and Human Services (HSS) and the DOJ to review the rescheduling of cannabis.

The White House has yet to confirm the status of the rescheduling proposal. While Jean-Pierre mentioned the proposal is with the DOJ, the department confirmed completing the review. It’s expected to have been forwarded to the White House Office of Management and Budget (OMB) for assessment before publication in the Federal Register for public input.

During a committee hearing last week, the head of the U.S. Drug Enforcement Administration  (DEA) declined to comment on the department’s recent cannabis rescheduling decision due to the ongoing rulemaking process.

Last month, the press secretary reiterated Biden’s support for cannabis decriminalization. She also stressed that HHS’s rescheduling recommendation to the DEA was grounded in evidence and science, echoing the administration’s principles.

Both Biden and Vice President Kamala Harris have increasingly vocalized their support for cannabis policy reform leading up to the November election. Additionally, the top House Democrat noted that the administration’s move to reschedule cannabis is a positive step but advocated for further congressional action, including passing Senate Majority Leader Chuck Schumer’s legalization bill.

Conversely, a GOP senator argued that cannabis serves as a “gateway drug” and criticized Democrats’ legalization efforts as promoting criminal behavior. He also expressed concerns about marijuana banking legislation facilitating increased drug use in the United States.

All that marijuana companies such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) can do at this point is to wait for the formal communication by the DEA regarding their stand on marijuana scheduling in light of the recommendation that the agency received from HHS.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of Dosing in Comprehensive GLP-1 Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, reported that dosing has begun in its 12-week animal study, WEIGHT-A24-1. The study is designed to model diabetes treatment and weight-loss effects of DehydraTECH(TM)-processed glucagon-like peptide 1 drugs and DehydraTECH-processed cannabidiol (“CBD”), both alone and in combination in diabetic preconditioned rats. According to the announcement, several new areas of investigation are being explored in this study, including evaluating whether DehydraTECH-processed oral GLP-1 drugs are more effective than non-DehydraTECH-processed oral GLP-1 drugs in reaching brain tissue, improving weight loss and improving control of blood sugar. The study will also evaluate whether adding CBD shows improved results. “In previous animal research with two other molecules, including CBD, Lexaria demonstrated through brain tissue examination that DehydraTECH processing enabled higher levels of drug delivery into brain tissue,” stated the company in the press release. “Study WEIGHT-A24-1 is designed to further validate whether DehydraTECH processing can similarly deliver higher quantities of GLP-1 drugs into brain tissue. Recent research has indicated ‘that a small peptide GLP-1R agonist penetrates the brain and activates a subset of GLP-1R–expressing neurons in the arcuate nucleus to produce weight loss.’ Lexaria believes that, if it can evidence that DehydraTECH processing of GLP-1 drugs can enable greater penetration into brain tissue, then this may help to explain how the GLP-1 drug(s) powered by DehydraTECH may be more effective at enhancing beneficial outcomes such as weight loss and blood sugar control. In turn, this could also potentially allow for lower dosing and a concomitant reduction in adverse side effects.”

To view the full press release, visit https://cnw.fm/mDkQ9

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery formulation and processing platform technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 41 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Marijuana Rescheduling Likely to Reduce Barriers to Research

The Biden administration’s move to reclassify cannabis as a less hazardous substance is anticipated to ease some of the limitations on research. However, experts caution that while the change will alleviate certain restrictions, it won’t eliminate all of them. Additionally, it may not necessarily reduce the potential risks associated with cannabis or enhance users’ understanding of those risks.

Currently, cannabis is categorized as a Schedule I substance, indicating it is deemed to have a high abuse potential and no recognized medical value. The proposed shift by the Biden administration aims to move cannabis to Schedule III, acknowledging its medical benefits to some extent.

This adjustment is significant as the Schedule I classification imposes stringent regulations that hinder scientific research on cannabis, despite its increasing availability due to changes in state laws. These regulations encompass various aspects such as reporting, storage and security requirements, governed by entities such as the Food and Drug Administration (FDA), the U.S. Drug Enforcement Administration (DEA), local authorities and the Institutional Review Board.

Neuroscientist Staci Gruber of Harvard Medical School and McLean Hospital draws attention to the onerous procedures that researchers must go through, including registering with the DEA and obtaining federal and state permits to perform studies on cannabis.

According to advocates, reclassifying the drug to Schedule III, alongside drugs such as Tylenol and ketamine, will be a significant change that could affect attitudes and viewpoints on the study of drugs in different categories. Gruber sees this change as particularly beneficial for aspiring researchers who will no longer require a Schedule I license, thus facilitating their entry into the field.

Similarly, Dr. Andrew Monte, associate director of Rocky Mountain Poison and Drug Safety, believes that the reclassification will foster more research on the therapeutic benefits and potential risks of marijuana, thereby enhancing the quality of research outcomes.

However, despite the reclassification, Gruber notes that the availability of marijuana for research purposes may not significantly increase. Historically, researchers were limited to obtaining cannabis from a single source: the University of Mississippi. Although the DEA has started approving additional sources since 2021, the accessibility of these sources remains limited, hindering researchers’ ability to study the products commonly used by patients and consumers.

Moreover, there is a lack of comprehensive information regarding the composition of marijuana products available on the market today. Studies suggest that the current THC levels, the primary psychoactive component in cannabis, are substantially higher than in previous decades, posing greater health risks.

Monte warns against overlooking the health risks associated with cannabis, despite its reclassification. He and his colleagues have observed various adverse effects in individuals, such as intoxication and cyclic vomiting syndrome, as well as psychiatric symptoms, including psychosis, leading to hospital visits. Despite the reclassification, addressing these risks requires ongoing surveillance and research efforts, which the reclassification alone may not fulfill.

When the DEA finally announces its cannabis rescheduling decision, entities such as Astrotech Corp. (NASDAQ: ASTC) could see new opportunities for business as their testing equipment starts attracting more interest from the marijuana research community.

NOTE TO INVESTORS: The latest news and updates relating to Astrotech Corp. (NASDAQ: ASTC) are available in the company’s newsroom at https://cnw.fm/ASTC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Three Changes That Could Happen Post-Marijuana Reclassification

The United States Drug Enforcement Administration (DEA) is planning to reclassify cannabis, marking a significant shift in American drug policy that could have widespread implications nationwide. Melba Pearson, a legal expert specializing in civil rights and criminal law, shared insights on the potential changes following the reclassification.

Working at Florida International University’s Jack D. Gordon Institute for Public Policy, Pearson directs prosecution projects, focusing on technical assistance, training and community engagement in prosecution. She previously served as deputy director at the American Civil Liberties Union of Florida.

Pearson noted the magnitude of the proposal, highlighting its potential impact despite not legalizing recreational cannabis outright. She noted the increasing number of states permitting recreational cannabis sales, suggesting that the reclassification could encourage more states to consider legalization.

The reclassification is expected to open doors for new research opportunities on cannabis, addressing past challenges in securing funding due to its classification. Pearson expressed hope that states would review criminal sentences related to cannabis use, potentially revisiting convictions and facilitating record expungement to support individuals’ rehabilitation.

Drawing parallels with sentencing disparities in drug offenses such as crack cocaine and cocaine, Pearson suggested that states might reconsider cannabis convictions deemed unjust in light of changing laws. Notably, possession of marijuana in Florida can still result in misdemeanor charges depending on the quantity, despite the legalization of medical marijuana through Amendment 2 in 2016.

Looking ahead, Florida voters will decide on recreational cannabis legalization in November, requiring a minimum of 60% support to pass the amendment.

A number of other states may hold public votes, with South Dakota currently gathering signatures to legalize marijuana for recreational use. In Nebraska, a cannabis advocacy group is collecting signatures in a bid to place two ballot proposals this year: one that would legalize medical marijuana and another that would permit commercial businesses to cultivate and sell it. The effort comes after two prior unsuccessful attempts.

Elected officials in other places, including Tennessee, are still hesitant to support marijuana use for either recreational or medical purposes. Republican speaker of the Tennessee Senate, Randy McNally, had previously declared that he would not back changes to state law until cannabis is reclassified by the federal government.

Nonetheless, the impending reclassification decision reflects ongoing shifts in public attitudes toward cannabis and could signal further changes in drug policy at both the state and federal levels. When federal reforms are enacted, the cannabis industry, including established enterprises such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) could revisit their roadmaps and find ways to leverage the improved regulatory landscape.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Software Effective Solutions Corp. (SFWJ) Subsidiary Looks to Ride Expansion Trend, Moving into Central American Cannabis Markets

  • The global textile industry is increasingly turning to hemp, celebrating the plant’s ability to enhance soil health, support biodiversity, suppress weeds, and increase yields
  • Central American expansion is part of MedCana’s broader strategy to strengthen its presence in the global cannabis and agricultural technology sectors 
  • MedCana is a pioneer in the integration of technology and agriculture, focusing on cannabis and emerging technologies

Worldwide, more farmers are opting to grow hemp because of its agricultural benefits. Leveraging that trend, Eko2o Environmental Solutions S.A.S., a majority-owned subsidiary of Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ), is expanding operations into Costa Rica and the broader Central American market (https://cnw.fm/RCohp). As the company moves forward with expansion plans, Eko2o provides invaluable insight and expertise gained from being at the forefront of agricultural innovation and offering cutting-edge solutions that enhance efficiency and sustainability in farming practices.

“Since its recent legalization in countries around the world, the global textile industry is increasingly turning to hemp, celebrating the plant’s ability to enhance soil health, support biodiversity, suppress weeds, and increase yields among subsequent crops — all while relying on little or no inputs,” stated a recent article (https://cnw.fm/xz9U5). “Fiber hemp holds strong sustainability potential, but as it gains popularity, it is vital that we look at how it is grown.

“This means taking on board lessons learned from other fiber crops, where heavy synthetic pesticide and fertilizer use have become the norm,” the article continued. “At this early stage, the industry has a unique opportunity to shape fiber hemp standards from the soil up, setting up systems that maximize measurable benefits for the climate, ecosystems, and communities.”

Factors contributing to the company’s decision to expand into these key markets are the region’s rich biodiversity, its progressive environmental policies, and a growing demand for sustainable agricultural practices. Eko2o’s strategic expansion plans include establishing partnerships with local organizations, setting up operations that will serve as centers for research and development, and introducing its state-of-the-art agricultural technology solutions to the market.

“Costa Rica and Central America are regions known for their commitment to environmental sustainability and high agricultural potential,” said Eko2o CEO Juan Ricardo Velez. “This makes them the perfect match for Eko2o’s mission and expertise. We are excited about the opportunity to collaborate with local farmers and businesses to promote sustainable agriculture that benefits both the economy and the ecosystem.”

This expansion is part of MedCana’s broader strategy to strengthen its presence in the global cannabis and agricultural technology sectors. Recently, the company has inked several key deals and completed strategic acquisitions that have positioned the company as a key player in the industry. As a MedCana subsidiary, Eko2o has established a reputation for offering state-of-the-art greenhouse infrastructure and agricultural technology solutions. The company is committed to enhancing the efficiency and sustainability of agricultural production in Colombia and beyond.

Operating under Software Effective Solutions Corp., MedCana is a pioneer in the integration of technology and agriculture, focusing on cannabis and emerging technologies. With a vision to revolutionize the industry through innovation, MedCana is dedicated to acquiring and partnering with companies that align with its mission of promoting sustainable and technologically advanced agricultural practices.

MedCana is committed to developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. These recent acquisitions reflect the company’s focus on scientific advancements and sustainable practices as it works to achieve the broader goal of leading the cannabis industry through strategic growth and pioneering research. The company is excited about the future prospects these new assets bring to its operations and the vast opportunities for innovation they unlock.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

More Than Just Green: Zoned Properties Inc. (ZDPY) Experts in Complexities of Opening a Cannabis Dispensary

  • With cannabis legalization exploding nationwide, there are now over 19,500 incorporated U.S. cities, town, and villages that will govern local cannabis regulations
  • Zoned Properties is comprised of a team of experts in cannabis zoning codes utilizing proprietary technology to identify premium cannabis dispensary locations
  • Focused on its dispensary landlord model, the company has listed its largest cultivation property in Arizona for sale for $16 million

The cannabis industry is flourishing, but opening a dispensary isn’t a walk in the park. Aspiring entrepreneurs face a maze of regulations and considerations beyond simply having a quality supply chain.

Unprecedented Geographic Growth

California sparked the green wave in 1996 by becoming the first state to legalize medical marijuana. Fast forward 16 years, and Colorado and Washington shattered another barrier in 2012, allowing recreational cannabis use. Since then, the domino effect has been undeniable, with 38 states now permitting medical marijuana and 24 embracing recreational use.

In 2010, public approval for legal cannabis was just 32%. Today, with industry sales nearing $40 billion annually, approval is 91%. With that, there are now over 19,500 incorporated U.S. cities, town, and villages that will govern local cannabis regulations.

Zoning Laws and Location

Unlike many businesses, cannabis dispensaries are heavily restricted by state and local zoning ordinances. Understanding these complex regulations is crucial. Some areas completely ban dispensaries, while others have strict limitations on location. Navigating these restrictions can be a minefield, requiring expertise in real estate and community planning codes.

Not long after Colorado and Washington made history, Zoned Properties (OTCQB: ZDPY) was formed for the purpose of capitalizing on the real estate component of the burgeoning cannabis market. The company assembled a team of real estate experts specialized in different market nuances and undergirded their experience by developing a cutting-edge technology that differentiates Zoned Properties from anyone else in the industry.

The history and future of the company is brilliantly summarized in a recent Bell2Bell podcast with Zoned Properties CEO and Chairman Bryan McLaren.

Knowing Your Market

Finding the right location goes beyond zoning. Just because marijuana is legal doesn’t mean there’s specific demand. Demographics, traffic patterns, and competitor saturation all influence success. Data analysis and market research are crucial to ensure a dispensary caters to a viable customer base.

Zoned Properties’ proprietary technology plots every parcel of land in every legal cannabis state to know the codes and zoning at every location. Furthermore, the system identifies areas of high consumer demand and low supply. In other words, a perfect location for a dispensary.

Zoned Properties doesn’t just find properties; they transform them. Their team of real estate and community planning experts navigate the complex world of zoning regulations to obtain “special use”, or “conditional use” permits necessary for properties to operate as cannabis dispensaries. This entitlement significantly increases a property’s value.

The Cannabis Friendly Landlord

The business model has changed some over the years, with ZDPY management identifying the best way to build value is through owning and renting dispensaries via long-term absolute-net lease agreements. To that end, the company intends to fill its coffers by positioning to sell its largest cultivation property in Chino Valley, Arizona, which it recently listed for $16 million.

In its March 2024 corporate presentation, Zoned Properties said it had $3.1 million in cash on hand. Add in another $16 million and that is an anomaly of cash for a company with a market capitalization around only $7 million.

The dilution-free capital from the sale will be deployed to continue aggressive dispensary expansion into states exploding with growth and demand, including Ohio and Illinois.

For more information, visit the company’s website at www.ZonedProperties.com.

NOTE TO INVESTORS: The latest news and updates relating to ZDPY are available in the company’s newsroom at https://cnw.fm/ZDPY

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Germany May Initiate Legal Adult-Use Cannabis Sales Via Regulations, Bypassing Standalone Law

Germany is progressing with the next stage of cannabis legalization by initiating a pilot program for commercial sales using an administrative process instead of waiting for legislators to pass a separate measure as initially anticipated. It has long been expected that lawmakers would introduce and approve additional sales bills to complete the second phase of legalization. However, the government is opting for a rulemaking approach, potentially expediting the implementation process.

Cannabis legalization was set in motion under a measure led by Germany’s Ministry of Health, which went into force in April 2024. This allows adults to use and grow marijuana and join clubs for access to the plant, with cooperative launches expected in July. Nonetheless, there is currently no established commercial sales road map.

According to a report from Tagesspiegel Background, the existing law provides regulatory flexibility to build upon the original reform. Germany’s Ministry of Agriculture has the authority to create regulations for a commercial pilot initiative, enabling adults to purchase marijuana in specific areas without requiring further legislative action.

However, this approach also raises the possibility of easier reversal by a future government. Nevertheless, in the short-term, expediting the sales process is possible. According to reports, representatives from the Agricultural Ministry have sent out a letter asking for comments by May 10, 2024, on possible rules on retail sales under a pilot initiative.

Karl Lauterbach, Germany’s health minister, who has been leading the government’s marijuana legalization efforts, mentioned to Bundestag members last year that the commercial sales program is under consideration. With legalization already in place, there is growing pressure to accelerate this process.

Previously, the Bundesrat representing different states attempted to block the legalization proposal enacted last September, but this effort failed. Bundesrat members later worked with Lauterbach and other government officials to find a compromise.

The first legalization framework was accepted by Germany’s cabinet in late 2022, but to uphold its international responsibilities, the government sought approval from the European Union. Hearings were held in 2022 to provide legislation that would remove the prohibition.

In November 2023, government representatives from various countries, including the United States, convened in Germany to discuss international cannabis policy as the host country pursued legalization.

A delegation of German legislators visited the United States in 2022, touring marijuana businesses in California to inform Germany’s approach to legalization. The visit followed a groundbreaking meeting between Netherlands, Germany, Malta and Luxembourg officials to discuss plans and obstacles related to recreational cannabis legalization.

The coalition government leaders revealed some details of their agreement to legalize cannabis in 2021 and declared that they had come to an agreement to eliminate prohibition.

Meanwhile, the drug control arm of the United Nations recently restated its stance that legalizing cannabis for nonscientific or nonmedical purposes violates international treaties. However, it acknowledged Germany’s government for scaling back its marijuana plans before the upcoming vote.

This expedited way to get adult-use cannabis sales underway is likely to be applauded by the wider marijuana industry, including major companies such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF), because as it would facilitate access to recreational marijuana for Germans who are interested in consuming the substance.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation

  • Lexaria, a global innovator in drug delivery platforms, just announced its newest relationship with the National Research Council of Canada (“NRC”)
  • Specific molecular characteristics of the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, processed with Lexaria’s patented DehydraTECH(TM) technology, will be evaluated
  • Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood compared to Rybelsus(R). This has potential for increased weight-loss and diabetic control
  • Lexaria’s management is confident that this partnership will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced a partnership with the National Research Council of Canada (“NRC”) that will pursue an applied research program to evaluate specific molecular characteristics of the company’s patented DehydraTECH(TM) technology processed with glucagon-peptide 1 (“GLP-1”) drug, semaglutide, related to its mode of action and performance (https://cnw.fm/tFjNC).

The work program will utilize simulated gastric fluid, mimicking conditions in the human gut. In addition, various testing methods will be employed, among them size exclusion chromatography (“SEC”), polyacrylamide gel electrophoresis (“PAGE”), dynamic light scattering (“DLS”), and matrix-assisted laser desorption ionization mass spectrometry (“MALDI MS”).

GLP-1 drugs have shown significant benefits in weight management and addressing diabetes. Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood than an unprocessed Rybelsus(R) tablet. The benefits also extend to doing away with painful injections, which are the norm with GLP-1 delivery.

Lexaria’s management believes this partnership could help fast-track the company’s push for the adoption of DehydraTECH with GLP-1 drugs. It will also be integral in showcasing the potential of the technology while inching the company closer to tapping into an industry projected to be valued at $133.5 billion by 2030 (https://cnw.fm/GjFj1).

“We are excited about our partnership with the NRC for the mode of action molecular characterization of DehydraTECH-GLP-1 drugs. This work program could potentially provide data to assist Lexaria’s efforts in partnering with the pharmaceutical industry for the most rapid introduction possible of DehydraTECH with GLP-1 drugs,” noted John Docherty, Lexaria’s president.

This partnership follows Lexaria’s resolve to double down on GLP-1 studies for the 2024 calendar year. It also follows the recent independent third-party ethics review board approval for its GLP-1 human pilot study #2, which seeks to explore the oral delivery of GLP-1 drugs. In addition, in March Lexaria announced details of its WEIGHT-A24-1 animal study which will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination (https://cnw.fm/Qdt0X).

Lexaria’s management is confident that by identifying the molecular behavior of DehydraTECH-processed pure semaglutide compositions, the findings will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year. In addition, it is hopeful that this could ultimately lead to alternative formulations with enhanced performance. The program is expected to be completed in early August, with results reported as soon as possible after that.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Marijuana Advocates See Rescheduling as Tool to Enact Reforms in Prohibitionist States

The anticipated reclassification of cannabis by the federal government to a less-dangerous category may not have an immediate effect on states where cannabis use for either recreational or medical purposes is still illegal. Nonetheless, cannabis legalization proponents see the federal shift as potentially influencing state policymakers who have been hesitant about endorsing cannabis.

Matthew Schweich, head of the Marijuana Policy Project, a prolegalization advocacy group, often encounters state legislators who express potential support but are reluctant due to federal illegality. While reclassification wouldn’t legalize cannabis outright, Schweich believes it could alleviate some concerns among state legislators, potentially making them more inclined to support legalization efforts.

The U.S. Drug Enforcement Administration’s proposal aims to move marijuana from Schedule I to III of the Controlled Substances Act. This shift would entail less-stringent regulation, though the process may not conclude until after the upcoming presidential election. In the interim, the proposed change could provide new arguments for proponents of ballot initiatives seeking cannabis legalization. Florida is set to vote on a constitutional change for recreational marijuana in November 2024. Similar votes are anticipated in South Dakota and Nebraska, where efforts are underway to legalize recreational cannabis and permit private companies to cultivate and distribute it.

Moreover, former police officer Mark Friese, now a criminal defense lawyer in North Dakota, is in favor of a program to legalize cannabis in the state. In his opinion, those efforts may greatly benefit from the federal reclassification.

However, not everyone is convinced of the impact of reclassification. Jackee Winters, leading a group in Idaho advocating for medical cannabis legalization, finds it challenging to gather support due to fear of legal repercussions.

The potential federal change may have a limited effect in states where marijuana is already legal for recreational or medical use. Still, advocates hope it could sway opinions in states with more restrictive laws or outright bans on cannabis.

In Georgia, although low-THC marijuana products have been allowed since 2015 for specific medical conditions, purchasing them legally only became possible last year. A federal reclassification could ease restrictions, allowing pharmacists to handle cannabis products much as they do any other prescription medication.

Meanwhile, in states such as Tennessee where elected officials are hesitant to support marijuana legislation, a federal reclassification could spark conversations. However, some, such as Senate Speaker Randy McNally, remain cautious, noting that many issues would persist even if marijuana were downgraded to Schedule III.

Kansas faced a similar scenario where attempts to legalize medical cannabis met strong opposition, particularly from law enforcement officials concerned about potential ramifications.

In Texas, limited access to low-THC marijuana products is allowed by law, but efforts to expand access have faced criticism. Similarly, in Wyoming, past efforts to decriminalize cannabis or legalize medical use have not gained traction.

Despite these challenges, there’s optimism among advocates that federal reclassification could ease resistance and encourage more legislators to seriously consider legalization. Apollo Pazell, who has been involved in previous legalization efforts, believes that resistance will diminish over time.

Existing cannabis companies such as SNDL Inc. (NASDAQ: SNDL) will probably wait for the reclassification process to be completed so that they can assess how they can realign their strategic direction in light of the evolving landscape at the federal level.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – CannaCon Names CannabisNewsWire, IBN as Media Partners for Upcoming 2024 Events

CannaCon, a global business-to-business (“B2B”) venue for cannabis businesses, marijuana entrepreneurs, investors and community partners, has selected CannabisNewsWire (“CNW”), a specialized communications platform for the cannabis sector and one of more than 60 brands powered by IBN, as the Official NewsWire for its upcoming CannaCon West Albuquerque; the event is slated for May 17–18, 2024. In addition, CannabisNewsWire and IBN will partner with CannaCon as official media partners for several upcoming events, including Midwest conferences scheduled on Aug. 16–17, 2024, in Albuquerque and on Oct. 3–4, 2024, in Cleveland. According to the announcement, IBN and CNW will use their comprehensive portfolio of communications tools to optimize virtual coverage, including a minimum of one syndicated article and one newsbreak distributed through IBN’s proprietary network of more than 5,000 strategic partners. IBN will also broadcast live updates featuring the events to its two-plus million social media likes, followers and subscribers. The coverage also includes featured placement of CannaCon events on event pages for both IBN and CNW. “CannaCon West Albuquerque looks forward to helping grow the west’s cannabis industry for years to come and to service business needs across a diverse range of requirements,” said CannaCon director of marketing Angela Grelle in the press release. “We are very pleased to have InvestorBrandNetwork and CannabisNewsWire on board as our media partners for the remainder of 2024. IBN’s world-class communications outreach and services will play a key role in elevating the visibility of our events and garnering greater interest across discrete geographies. We look forward to working side-by-side with their highly professional and dedicated team. This is a must-attend event for anyone interested in the cannabis sector as well as active and curious consumers.”

To view the full press release, visit https://cnw.fm/FOMU1

About CannaCon

CannaCon is a distinctive conference company dedicated to creating and strengthening lifelong partnerships within the emerging cannabis industry to showcase industry products, people, innovations, and technology. Leveraging its history, networks, and deep expertise in the cannabis space, the conference develops and hosts industry-leading events that cultivate business values through education and responsible community involvement in this specialized domain. To learn more about the company, please visit www.CannaCon.org.

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN